Peripheral-type benzodiazepine-binding sites in platelets of schizophrenics with and without tardive dyskinesia
References (33)
Trends Neurosci.
(1985)- et al.
Biochem. Pharmac.
(1982) - et al.
Biochem. Pharmac.
(1984) - et al.
Eur. J. Pharmac.
(1981) - et al.
Eur. J. Pharmac.
(1986) - et al.
Eur. J. Pharmac.
(1985) - et al.
Eur. J. Pharmac.
(1982) - et al.
Brain Res.
(1979) - et al.
Brain Res.
(1982) - et al.
Life Sci.
(1985)
Life Sci.
(1984)
Clin. Neuropharmac.
(1982)
Br. J. Psychiat.
(1973)
Am. J. Psychiat.
(1973)
Science
(1984)
Am. J. Psychiat.
(1982)
Cited by (26)
TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward
2019, Pharmacology and TherapeuticsCitation Excerpt :These studies may provide important information that may help the interpretation of current TSPO-PET findings. As far back as 1986, there were studies examining the levels of TSPO in platelets from schizophrenia subjects (Gavish et al., 1986; Weizman et al., 1986). Two different studies showed that the maximal number of [3H]PK11195 binding sites (Bmax) in platelets from untreated schizophrenia subjects did not differ from age-matched healthy controls.
The translocator protein (18 kDa) and its role in neuropsychiatric disorders
2017, Neuroscience and Biobehavioral ReviewsThe peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development
2006, Pharmacology and TherapeuticsLigands for peripheral benzodiazepine binding sites in glial cells
2005, Brain Research ReviewsDecreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patients
2003, Journal of Psychiatric Research
Copyright © 1986 Published by Elsevier Inc.